Frontline HER2+ Therapy: Why “Best Drug First” May Matter More Than Sequencing

Up to 30% of patients never reach second-line therapy.

This clip tackles the central question:
Should we save T-DXd — or lead with it?

Key themes:
• Real-world attrition after first line
• Tumor biology vs clinical risk
• Why waiting may cost patients their best option